- Coordinator
- Universita Degli Studi Di Milano, Italy
- Runs
- 1 February 2024 to 31 January 2028
- Status
- Running
- EU funding
- €2.7m
- Total cost
- —
- Partners
- 19 organisations in 7 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101119795
What the project is doing
In the project's own words, from its summary on CORDIS.
Bacterial infections are a societal burden with profound medical and socio-economic impacts. Although antibiotics can be effective, the continuous emergence of bacteria with antimicrobial resistance calls for the introduction of novel therapeutics. In this regard, glycoconjugate vaccines (GV) hold a prominent role in the fight against AMR bacterial strains. They are based on the chemical conjugation of one or more pathogen-associated saccharide antigens to immunogenic carriers, leading to a long-term protective immunity.
ACINETWORK will focus on the development of GV against severe and life-threatening infections caused by antimicrobial resistant Acinetobacter baumannii strains, which are a major cause of nosocomial diseases and for which no vaccine exists. ACINETWORK wants to overcome the limitations of currently licensed GV, due to highly heterogeneous composition and batch wise variability, by innovatively using structurally-defined synthetic oligosaccharide antigens to develop GV with well-defined composition, higher purity and better safety profiles.
The manufacturing of such GV is also more rapid and cost-effective. Thus, this project will set synthesis and testing pipelines that will serve as the prototype for the development of GV against other bacteria. The ACINETWORK consortium comprises universities and SMEs with a unique complementary expertise, ranging from carbohydrate chemistry to nanotechnology, immunology and microbiology, which garantees the realization of the new GV.
The goal of ACINETWORK is to also forge 10 young experts in the design of these novel medical solutions with an integrated training program, which will equip them with a large battery of scientific and transferable skills. The multidisciplinarity of the consortium ensures a fertile and stimulating environment in which these young researchers will acquire unique competencies in vaccine design, development and production, which will be central at putting Europe at the forefront of GV.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Milano | Milano | Italy | Coordinator |
| The Governors of the University of Alberta | Edmonton | Canada | Associatedpartner |
| European Molecular Biology Laboratory | Heidelberg | Germany | Associatedpartner |
| Freie Universitaet Berlin | Berlin | Germany | Associatedpartner |
| Glycouniverse GmbH & Co. Kommanditgesellschaft Auf Aktien | Potsdam | Germany | Participant |
| Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eV | Munchen | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic Biomagune | San Sebastian | Spain | Participant |
| Instituto De Salud Carlos Iii | Madrid | Spain | Participant |
| Universidad Del Pais Vasco/ Euskal Herriko Unibertsitatea | Leioa | Spain | Associatedpartner |
| Universidad Nacional De Educacion a Distancia | Madrid | Spain | Associatedpartner |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Universite De Montpellier | Montpellier | France | Associatedpartner |
| Associazione Hand in Hand | Nemi | Italy | Associatedpartner |
| Consiglio Nazionale Delle Ricerche | Roma | Italy | Associatedpartner |
| Fratagene Therapeutics srl | Rome | Italy | Associatedpartner |
| Idea75 SRL | Bari | Italy | Associatedpartner |
| Universita Degli Studi Di Firenze | Florence | Italy | Participant |
| Attana AB | Stockholm | Sweden | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI